Are you sure you want to leave?
25 August 2019
From 13 June to 16 June 2019, Vifor Pharma was at the 56th ERA–EDTA Congress in Budapest, Hungary. We hosted a disease state education booth and sponsored an educational symposium with the aim of enhancing awareness of secondary hyperparathyroidism (SHPT) and the limitations of current treatments.
Physicians who visited our booth, which we set up in one of the e-campus learning stations, were able to:
The booth was a success, attracting lots of attention and stimulating passionate discussions.
Entitled ‘Navigating CKD–MBD in 2019: expert perspectives’, the symposium was chaired by Professor Jordi Bover* and attracted a very attentive audience.
Consisting of two presentations, the symposium began with an introduction from Professor Bover, who outlined SHPT and its pathogenesis. This was followed by the first presentation, delivered by Professor Markus Ketteler,† who explored the current concepts and controversies inherent to the management of SHPT in both predialysis and dialysis patients.
The second presentation was given by Associate Professor Marc Vervloet,‡ who considered the challenges associated with the management of hyperphosphataemia, including appropriate phosphate targets and current and future strategies that may help patients achieve them.
If you missed the symposium, you can watch the highlights below.
*Clinical Professor of Nephrology; Nephrology Department, Fundació Puigvert, Universitat Autònoma de Barcelona; Catalonia, Spain.
†Head of General Internal Medicine and Nephrology; Robert-Bosch-Krankenhaus; Stuttgart, Germany.
‡Associate Professor; Department of Nephrology, VU University Medical Center; Amsterdam, the Netherlands
You are viewing a website from Vifor Pharma. This material is only intended for healthcare professionals (“HCPs”) from Europe. If you are not the intended audience, please leave this website. By checking the box, you acknowledge that you are a HCP from Europe. Approval conditions for products may vary from country to country. Before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.